1. Introduction {#s0005}
===============

Although the treatment of acute myocardial infarction (MI) has improved over the years, the mortality of patients in cardiogenic shock complicating MI remains high even with the use of primary percutaneous coronary intervention (PCI) and has not changed in decades [@bb0005], [@bb0010]. However, over the past decade, rates of cardiogenic shock developing during hospitalization as well as in-hospital mortality associated with shock have decreased; increased PCI rates for these critically ill patients may explain these secular trends [@bb0015].

Beyond the use of PCI, intra-aortic balloon pump (IABP) implantation has widely been used as an adjuvant treatment for cardiogenic shock in patients with acute MI based on the beneficial effect of aortic diastolic inflation and rapid systolic deflation, improving myocardial and peripheral perfusion and reducing afterload and myocardial oxygen consumption [@bb0020], [@bb0025]. The evidence base supporting IABP in cardiogenic shock use is mixed; in a recent meta-analysis [@bb0030], the use of IABP in patients with ST-segment elevation MI (STEMI) with cardiogenic shock treated was associated with a survival benefit [@bb0030]. However, on an individual level the data are less clearly supportive [@bb0035]. Notably, a randomized trial, the Intraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock (IABP-SHOCK II) study showed no improvement in survival using IABP in patients with MI and cardiogenic shock [@bb0040]. However, in this trial the patients represented a rather moderate-risk cohort with a substantially lower short-term mortality compared to those in other trials [@bb0010], [@bb0045]. Additionally, in IABP-SHOCK II, there was observed a favorable trend with IABP in younger patients and in those with a first MI. Accordingly, in an effort to examine this question in more detail, we used data from the Western Denmark Heart Registry (WDHR) to compare short- and long-term mortality among (A) STEMI patients with and without cardiogenic shock and (B) STEMI patients with cardiogenic shock with and without the use of IABP. It was our hypothesis that risk for mortality related to cardiogenic shock in this "real world" cohort of patients would be substantial, and that IABP use would reduce risk significantly compared to conservative management without IABP.

2. Patients and methods {#s0025}
=======================

2.1. Setting and design {#s0030}
-----------------------

The study was conducted using WDHR for patients treated at Odense University Hospital with a catchment population of 1.2 million inhabitants. A detailed description of the database has been reported previously [@bb0050].

2.2. Patients and procedures {#s0035}
----------------------------

Primary PCI became the recommended treatment for STEMI in Denmark in 2003 after pivotal trials supported this approach [@bb0055]. To be eligible for primary PCI, patients must generally meet the following criteria: 1) symptoms present less than 12 h from onset of pain to time of catheterization, and 2) ST-segment elevation (at least 0.1 mV in two or more standard leads or v4--v6, or at least 0.2 mV in two or more contiguous precordial leads (v1--v3) or a presumed new left bundle-branch block. We used the WDHR to identify all primary PCIs performed from January 1, 2002 through December 31, 2010. A patient was considered in cardiogenic shock if systolic blood pressure was \< 90 mm Hg with the need of infusion of catecholamines to maintain the blood pressure, had clinical signs of pulmonary congestion, and had impaired end-organ perfusion (cold, clammy skin, altered mental status) or the use of IABP within the first 24 h of admission. Primary PCI was performed according to the standard. A glycoprotein IIb/IIIa receptor blocker was administered at the operator\'s discretion. The post-intervention antiplatelet regimen included lifelong acetylsalicylic acid (75 mg once daily) and clopidogrel with a loading dose of 300 mg followed by maintenance with 75 mg daily. The recommended duration of clopidogrel treatment was 12 months.

2.3. Endpoints {#s0040}
--------------

The endpoint was time to all-cause mortality. Data on mortality status were obtained from the Danish Civil Registration System; this system has data to support accuracy [@bb0060], [@bb0065].

The Danish National Health Service provides universal tax-supported health care, guaranteeing residents free access to general practitioners and hospitals. The Danish Civil Registration System has kept electronic records on gender, birth date, residence, emigration date, and vital status changes since 1968, with daily updates; the 10-digit civil registration number assigned at birth and used in all registries allows for accurate record linkage. The Civil Registration System provided vital status data for our study participants and minimized loss to follow-up.

2.4. Statistical methods {#s0045}
------------------------

Continuous variables were presented as medians with inter quartile range (IQR 25th, 75th) or mean ± 1 standard deviations (SD). Medians were compared using the Mann--Whitney *U* test, and means were compared using the unpaired *t* test. Categorical variables were presented as numbers and percentages. Distributions of categorical variables were compared using the Chi-square test. We counted endpoint events that occurred during the follow-up period and compared rates for the two groups. Follow-up began on the date of primary PCI procedure and continued until date of death, December 31, 2010 or after 5 of years follow-up (to ensure at least 10% of the study population at risk), whichever came first.

We constructed Kaplan--Meier curves for patients with cardiogenic shock and without cardiogenic shock, and patients with cardiogenic shock were stratified according to treatment with an IABP or not. Cox proportional hazards regression analysis was used to estimate the hazard ratio (HR) for mortality. Crude and adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) were computed. Potential confounders associated with time to death in the univariable Cox regression analysis were included in the multivariable Cox regression model. Thus, in the final model, we adjusted for age, gender, diabetes mellitus, previous MI, creatinine clearance \< 60 mL/min, treatment with glycoprotein IIb/IIIa receptor blocker, anterior MI/bundle-branch block MI, multivessel disease and procedure time. All data analyses were carried out using SPSS software version 20. A two-sided *p* value \< 0.05 was considered significant.

3. Results {#s0050}
==========

3.1. Study population {#s0055}
---------------------

A total of 4601 consecutive patients were treated with primary PCI for STEMI or bundle-branch block MI at Odense University Hospital between January 1, 2002 and December 31, 2010. Mortality data were not available for 85 patients, who were foreign citizens and were excluded. Patients undergoing a later primary PCI for acute MI after the first index procedure (n = 223) were excluded. Thus, the final study cohort consisted of 4293 patients, of whom 286 (6.7%) had cardiogenic shock and 4007 (93.3%) were without cardiogenic shock.

Baseline characteristics of patients with STEMI and cardiogenic shock and patients without cardiogenic shock are shown in [Table 1](#t0005){ref-type="table"}. There were differences in several baseline characteristics and risk factors between STEMI patients with and without cardiogenic shock, as patients with STEMI and cardiogenic shock were older, and more likely to have diabetes mellitus, reduced creatinine clearance, previous MI and previous CABG. Also, patients with cardiogenic shock more often had multi-vessel disease, anterior MI or bundle-branch block MI, a lower pre and post intervention TIMI flow and a longer procedure time ([Table 2](#t0010){ref-type="table"}).Table 1Characteristics of STEMI patients with cardiogenic shock versus without cardiogenic shock.With cardiogenic shockValid casesWithout cardiogenic shockValid cases*p* value (with vs. without cardiogenic shock)With cardiogenic shock and without IABPWith cardiogenic shock and with IABP*p* value (cardiogenic shock with versus without IABP)Number of patients286400721571Male gender --- no. (%)201 (70.3)2862939 (73.3)40070.258143 (66.5)58 (81.7)0.015Age --- years (inter-quartile range)71.0 (60.8--77.0)28664.0 (55.0--74.0)4007\< 0.00173.0 (64.0--80.0)62.0 (53.0--69.0)\< 0.001Family history --- no. (%)53 (21.8)2431433 (37.2)3853\< 0.00140 (21.9)13 (21.7)0.975Smoking --- no. (%)89 (50.0)1781725 (46.6)37020.37468 (54.4)21 (39.6)0.071Body mass index --- kg/m^2^ (inter-quartile range)25.7 (23.7--27.7)11126.2 (24.0--29.1)26190.07625.5 (23.0--28.3)25.8 (24.7--26.5)0.737Diabetes mellitus --- no. (%)37 (12.9)286269 (9.2)40070.03729 (13.5)8 (11.3)0.629Hypertension --- no. (%)83 (31.6)2631316 (33.3)39560.56963 (32.1)20 (29.9)0.727Previous coronary artery bypass grafting --- no. (%)8 (2.8)28186 (2.1)40010.0017 (3.3)1 (1.4)0.410Previous percutaneous coronary intervention --- no. (%)14 (5.3)264277 (7.0)39400.28410 (5.0)4 (6.2)0.698Previous myocardial infarction --- no. (%)48 (17.9)268447 (11.3)39470.00138 (18.8)10 (15.2)0.501Lipid-lowering therapy --- no. (%)64 (24.2)264807 (20.4)39470.14043 (21.6)21 (32.2)0.081Glycoprotein IIb/IIIa receptor blocker --- no (%)93 (34.0)2691685 (45.2)37260.00160 (29.6)33 (50.0)\< 0.001Killip class --- no. (%)2793921\< 0.0010.003I100 (35.8)3635 (92.7)85 (40)15 (21)II23 (8.2)188 (4.8)20 (10)3 (4)III27 (9.7)98 (2.5)20 (10)7 (10)IV129 (46.2)0 (0.0)84 (40)45 (64)Blood pressure --- mm Hg (inter-quartile range)Systolic90.0 (80.0--105.5)228120.0 (105.0--140.0)3027\< 0.00191.0 (80.0--105.5)80.0 (74.3--100.0)0.042Diastolic60.0 (50.0--65.0)22170.0 (60.0--80.0)3006\< 0.00160.0 (50.0--65.0)60.0 (50.0--70.0)0.144Table 2Procedure characteristics of STEMI patients with cardiogenic shock versus without cardiogenic shock.With cardiogenic shockValid casesWithout cardiogenic shockValid cases*p* value (with vs. without cardiogenic shock)With cardiogenic shock and without IABPWith cardiogenic shock and with IABP*p* value (cardiogenic shock with versus without IABP)Number of patients286400721571Infarct related artery --- no. (%)2753901\< 0.0010.021 Left anterior descending artery --- no. (%)110 (40.0)1679 (43.0)81 (39.3)29 (42.0) Left circumflex artery --- no. (%)30 (10.9)552 (14.2)25 (12.1)5 (7.2) Right coronary artery --- no. (%)78 (28.4)1605 (41.1)65 (31.3)13 (18.8) Left main --- no. (%)57 (20.7)65 (1.7)35 (17.0)22 (31.9)Anterior STEMI[a](#tf0005){ref-type="table-fn"} or BBBMI[b](#tf0010){ref-type="table-fn"} --- no. (%)155 (56.6)2751687 (43.8)4366\< 0.001108 (52.4)47 (69.1)0.016Multivessel disease --- no. (%)184 (67.4)2731722 (44.1)3903\< 0.001142 (48.3)42 (64.6)0.519Pre-intervention TIMI flow --- no. (%)27340380.0100.016 Grade 0170 (62.3)2134 (54.8)124 (60.8)46 (66.7) Grade 121 (7.7)243 (6.2)11 (5.4)10 (14.5) Grade 228 (10.3)674 (17.3)22 (10.8)6 (8.7) Grade 354 (19.8)846 (21.7)42 (23.0)7 (10.1)Final TIMI flow --- no. (%)2733897\< 0.0010.156 Grade 022 (8.1)111 (2.8)18 (8.8)4 (5.8) Grade 111 (4.0)42 (1.1)11 (5.4)0 (0.0) Grade 211 (11.4)225 (5.8)21 (10.3)10 (14.5) Grade 3209 (76.6)3519 (90.3)154 (75.5)55 (79.7)Lesion length --- mm15.0 (10.0--20.0)27015.0 (10.0--20.0)40010.35915.0 (10.0--20.0)15.0 (10.0--20.0)0.485Reference segment --- mm3.4 (3.0--3.8)2693.2 (3.0--3.6)39650.0843.2 (3.0--3.6)3.5 (3.1--3.8)0.001Sapheneous vein graft --- no. (%)0 (0.0)27414 (0.4)39020.3210 (0.0)0 (0.0)--Stent length --- mm18.0 (13.0--23.0)23818.0 (14.0--23.0)36210.73718.0 (13.0--24.0)18.0 (15.0--23.0)0.280Type of stent --- no. (%)28539520.2030.005 POBA only49 (17.2)417 (10.6)40 (18.6)9 (12.7) Bare metal stent103 (36.1)1229 (31.1)86 (40.2)17 (23.9) Drug eluting stent133 (46.7)2306 (58.4)88 (41.1)45 (63.9)Max balloon pressure --- atm16.0 (14.0--18.0)26116.0 (14.0--18.0)37860.61416.0 (14.0--18.0)16.0 (14.0--18.0)0.792Max balloon diameter --- mm3.5 (3.2--3.8)2613.5 (3.2--3.8)37840.9443.4 (3.2--3.8)3.7 (3.3--4.0)0.004Procedure time --- minutes (inter-quartile range)21.0 (15.0--41.0)28516.0 (10.0--26.0)3991\< 0.00120.0 (13.0--34.0)30.5 (19.0--51.0)\< 0.001Flouro time --- minutes (inter-quartile range)8.4 (5.5--15.1)2736.6 (4.0--11.5)3954\< 0.0017.9 (5.1--14.9)10.1 (6.4--16.1)0.048Contrast --- mL (inter-quartile range)110.0 (79.0--200.0)4731100 (75.0--175.0)39370.115100.0 (70.0--200.0)135.0 (100.0--200.0)0.052[^1][^2]

Among STEMI patients with cardiogenic shock, IABP was used in 71 (25%) patients. STEMI patients with cardiogenic shock treated with IABP were younger, more often male, and had a lower systolic blood pressure compared to patients with cardiogenic shock without IABP treatment ([Table 1](#t0005){ref-type="table"}).

3.2. Mortality {#s0060}
--------------

The median follow-up interval was 3.3 years (25th--75th percentile: 1.4--5.0 years), with a 30-day cumulative mortality of 8.0% (n = 495), one-year mortality of 495 (11.7%) and five-year mortality of 22.0% (n = 768). Among patients with STEMI with cardiogenic shock and without cardiogenic shock, 30-day cumulative mortality was 57.3% (n = 164) and 4.5% (n = 179), respectively (log-rank p \< 0.001); one-year cumulative mortality was 60.7% (n = 173) and 8.2% (n = 322), respectively (log-rank p \< 0.001); five-year cumulative mortality was 65.0% (n = 181) and 18.9% (n = 587), respectively (log-rank p \< 0.001). Short and long term cumulative survival are shown in [Fig. 1](#f0005){ref-type="fig"}. After adjustment for covariates associated with mortality (see [Statistical methods](#s0045){ref-type="sec"}), STEMI with cardiogenic shock was associated with increased mortality compared to STEMI without cardiogenic shock after 30 days \[adjusted HR = 12.89, 95% CI: 9.97--16.66\], one-year \[adjusted HR = 8.83, 95% CI: 7.06--11.05\] and five-year \[adjusted HR = 6.39, 95% CI: 5.22--7.81\] ([Table 3](#t0015){ref-type="table"}).Fig. 1Kaplan--Meier survival curves for consecutive patients with STEMI with and without cardiogenic shock.Table 3Crude and adjusted hazard ratio of covariates associated with one-year mortality in Cox regression analysis.Valid casesCrude hazard ratio\
(95% CI)*p* valueAdjusted hazard ratio\
(95% CI)*p* valueCardiogenic shock13.04 (10.82--15.72)\< 0.0018.80 (7.06--11.05)\< 0.001Female gender41161.50 (1.25--1.81)\< 0.0010.96 (0.78--1.06)0.683Creatinine clearance \< 60 mL/min41164.83 (4.05--5.76)\< 0.0011.90 (1.53--2.37)\< 0.001Age --- years41161.07 (1.06--1.08)\< 0.0011.05 (1.04--1.06)\< 0.001Diabetes mellitus41162.30 (1.83--2.87)\< 0.0011.90 (1.47--2.46)\< 0.001Previous myocardial infarction40431.91 (1.52--2.40)\< 0.0011.56 (1.19--2.05)0.001Glycoprotein IIb/IIIa receptor blocker38260.46 (0.38--0.57)\< 0.0010.66 (0.53--0.82)\< 0.001Multivessel disease40112.50 (2.07--3.01)\< 0.0011.44 (1.15--1.79)0.001Anterior MI/BBBMI40111.35 (1.13--1.62)\< 0.0011.23 (1.03--1.53)0.022Procedure time --- minutes41001.01 (1.01--1.02)\< 0.0011.00 (1.00--1.01)0.166

When stratifying patients with STEMI and cardiogenic shock into two groups with (1) treatment with IABP and (2) no treatment with IABP cumulative mortality rates were: 30-day cumulative mortality was 32.4% (n = 23) and 65.6% (n = 141), respectively (log-rank p \< 0.001); one-year cumulative mortality was 33.8% (n = 24) and 69.9% (n = 149), respectively (log-rank p \< 0.001); and five-year cumulative mortality was 48.8% (n = 26) and 73.4% (n = 155), respectively (log-rank p \< 0.001). Short term cumulative survival is shown in [Fig. 2](#f0010){ref-type="fig"}. After adjustment for covariates, treatment with IABP in patients with STEMI and cardiogenic shock was associated with a lower mortality compared to STEMI with cardiogenic shock without IABP support after 30 days \[adjusted HR = 0.45, 95% CI: 0.26--0.79\], one-year \[adjusted HR = 0.48, 95% CI: 0.28--0.83\] and five-year \[adjusted HR = 0.5, 95% CI: 0.30--0.85\].Fig. 2Kaplan--Meier survival curves for consecutive patients with STEMI and cardiogenic shock with and without the use of intra-aortic balloon pump.

4. Discussion {#s0015}
=============

In studies of cardiogenic shock complicating STEMI, rates of mortality vary widely [@bb0020]. Additionally, reported efficacy of widely used therapies such as IABP in these studies has been variable [@bb0020], [@bb0070]. However, current guidelines of the European Society of Cardiology have downgraded IABP use in patients with cardiogenic shock complicated by myocardial infarction (class 2B) [@bb0025]. The downgrading is primarily due to the results from the IABP-SHOCK II trial [@bb0040]. Despite this fact, IABP use remains in wide use, driven by substantial anecdotal evidence as well as meta-analytic results [@bb0030].

Our study indicates that among STEMI patients treated with primary PCI in a real world clinical setting, the presence of cardiogenic shock was associated with increased short-and long-term mortality compared to STEMI patients without cardiogenic shock. Importantly, use of IABP support in STEMI patients with cardiogenic shock was associated with significantly reduced mortality.

The incidence of cardiogenic shock was 6.7% in our registry, which included all consecutive STEMI patients treated with primary PCI, was similar to the results of several previous studies [@bb0005], [@bb0075]. Additionally, overall 30-day and 5-year mortality rate of \~ 60% is in accordance with other studies [@bb0005], [@bb0010], [@bb0045], [@bb0075], and in line with the assumption that the highest mortality of cardiogenic shock is during the first weeks after the shock appears. Importantly, 30-day mortality rate of 57% in our study was considerably higher compared to the results from IABP-SHOCK II trial, which had 30-day mortality of \~ 40% [@bb0040]. The higher mortality in our study may reflect a high risk cohort e.g. there was a high number of patients with left main disease in cardiogenic shock needing IABP. IABP-SHOCK II was the first adequately powered randomized controlled study of 600 patients with cardiogenic shock complicating acute MI. In this randomized multicenter study, the patients in cardiogenic shock underwent early revascularization, best medical therapy and were randomly assigned to IABP. In the IABP-SHOCK II trial [@bb0040], there was no difference in 30-day mortality, renal function or attenuation in lactate or C-reactive protein levels between patients treated with IABP compared to those without [@bb0040]. However, important caveats regarding differences between our study and IABP-SHOCK II exist. For example, a quarter of the patients in IABP-SHOCK II had serum lactate \< 2.0 mmol/L which indicates that the patients represented a moderate-risk cohort and \~ 10% of the patients randomized to optimal medical therapy had a cross-over and were treated with an IABP.

The mortality reduction of IABP in our study is in line with a recent meta-analysis which included prospective and retrospective cohort studies [@bb0030]. In contrast, analyzing data from the Euro Heart Survey Programme (EHS PCI) from the European Society of Cardiology including 653 patients with STEMI and non-STEMI, Zeymer et al. reported higher in-hospital mortality in the 25% of cardiogenic shock patients treated with IABP in comparison to the non-IABP group (56.9% versus 36.1%, *p* = 0.0004). In multivariate analysis including parameters such as age, gender, mechanical ventilation, severity of coronary artery disease, diabetes, renal failure and history of prior myocardial infarction, IABP use was not independently associated with mortality, although the corresponding *p*-value of 0.07 can be interpreted as a trend [@bb0080]. This is in contrast to our registry results, the opposite was found with a significant lower mortality rate in cardiogenic shock patients supported with IABP. Of course, important selection bias may be present in both registries e.g. operator\'s discretion for using IABP, the definition of cardiogenic shock, and difference in baseline characteristics of the patients.

It is worthwhile to discuss 30-day and 1 year mortality of patients with and without cardiogenic shock in our analysis. In-hospital mortality after STEMI in patients without cardiogenic shock has been reduced to \< 10% in the last decades [@bb0085]. This is mainly attributable to optimal interventional and drug treatment in the acute and subacute phase; indeed we observed quite similar results. In contrast to the clinical outcome in STEMI patients with hemodynamic stability, 30-day mortality of cardiogenic shock complicating STEMI remains high with rates of approximately 50% [@bb0005]. Thus, mortality related to cardiogenic shock has not changed substantially in nearly two decades [@bb0010], and studies focused on improved myocardial support, reperfusion, and protection in this population are critically needed. One option is alternative modes of support, such as the use of percutaneous left ventricular assist devices (LVAD). The prospective, randomized, open-label, multicenter, controlled Danish Cardiogenic Shock Trial (DanShock) \[ClinicalTrials.gov identifier: NCT01633502\] is ongoing and will assess whether the Impella cVAD™ LVAD treatment is beneficial for the treatment of cardiogenic shock.

4.1. Limitations {#s0065}
----------------

The validity of our findings depends on data quality and the ability to control for potential confounding. Like all observational studies, our study is prone to biases related to unmeasured factors. Bias due to unknown variables cannot be eliminated e.g. peripheral vascular disease or smaller peripheral vasculature. Our design is based on computerized registries with complete coverage, allowing study of a well-defined, large population with complete follow-up. That said, within the context of these limitations, it would appear that selection of patients to receive IABP support in our dataset led to more favorable outcomes, indeed a finding worth pointing out. We did not have systematic access to duration of inotropic support, serum lactate or information about left ventricular ejection fraction. We also lacked data on causes of mortality, however, in a previous STEMI cohort from Western Denmark Heart Registry, we found early causes of death were typically due to a cardiac reason: the 1-year mortality reason was cardiac in the great majority [@bb0090].

5. Conclusion {#s0020}
=============

In STEMI patients, cardiogenic shock was associated with increased short- and long-term mortality compared to STEMI patients without cardiogenic shock. IABP balloon support in STEMI patients with cardiogenic shock was associated with improved outcome. Given that the mortality rate of those suffering cardiogenic shock after STEMI has not changed substantially over the past 2 decades, more studies focused on the optimal care of this high-risk patient population are warranted.
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[^1]: ST-segment elevation myocardial infarct.

[^2]: Left bundle branch block.
